Senate Health and Welfare advances opioid‑abatement appropriation after heated syringe‑service debate

The Senate Health and Welfare committee on Tuesday advanced an appropriation bill allocating settlement and special‑fund dollars for opioid prevention, intervention, treatment, recovery and related harm‑reduction services, after members debated whether to include a $850,000 syringe‑service program appropriation.

Legislative staff said the bill would appropriate $8,100,000 and shift about $1,400,000 within the opioid‑abatement special fund for fiscal 2027, and would appropriate $640,000 from the substance misuse prevention fund. A staff presenter described the measure as an annual appropriation tied to the state’s declining settlement stream and noted one outstanding Purdue Pharma settlement could add an uncertain additional sum.

Committee members pressed staff and public‑health representatives about the syringe‑service program (SSP) line, which several members said has coincided with visible syringes in parks, lawns and along roadways. “I’ve had them out of my lawn in the front of my house before,” one member said, urging clearer requirements for collection and disposal to protect children and public spaces. An agency representative and a service‑provider speaker responded that SSPs do more than distribute syringes: they provide counseling, naloxone distribution, wound care, test strips and connections to treatment, and they also accept returned syringes when clients bring them back.

Agency staff said about $850,000 for SSPs was appropriated in the prior fiscal cycle but much of that money has not yet been obligated or reimbursed to grantees; providers have been spending in anticipation of reimbursement. The committee heard that roughly $1,200,000 tied to syringe services had not been obligated at the time of discussion, and that administrative and grant‑processing delays have contributed to funds not being disbursed.

Legislative counsel explained amendment language the committee considered: it adds an equity advisory consult, requires applicants for ongoing funding to include a sustainability plan, pauses acceptance of new funding proposals outside pre‑identified annual priorities for the next year, and clarifies that settlement funds must be used for opioid‑related prevention, treatment, recovery, harm reduction and co‑occurring mental‑health or substance‑use disorders secondary to opioid use disorder. Counsel also said the Attorney General’s office will be consulted when the advisory committee and the Department of Health offer divergent recommendations.

Some members urged statutory or programmatic fixes that would strengthen syringe return and disposal, including proposals discussed at length such as return‑for‑incentive programs, targeted disposal contracts, or feasibility studies to explore extended producer responsibility for sharps disposal. Service providers and panelists urged starting by asking existing providers (for example, Howard Center and local mental‑health centers) what would be practical and effective.

After discussion, a motion to move the bill as amended was made and seconded; the clerk recorded affirmative votes from multiple senators and the committee moved the bill forward. The committee also directed staff reporting and quarterly monitoring language intended to improve transparency around fund use and grant disbursement.

What’s next: the committee advanced the bill as amended; the measure will proceed through the legislative process with the amendments and reporting requirements attached. The transcript shows additional follow‑up items for staff and potential floor amendments from members seeking statutory changes to syringe‑service requirements.